Open AccessA Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer
Author(s) -
Fred R. Hirsch,
Fairooz F. Kabbinavar,
Tim Eisen,
Renato Martins,
F. Schnell,
Rafał Dziadziuszko,
Katherine Richardson,
Frank C. Richardson,
Bret Wacker,
David Sternberg,
Jason Rusk,
Wilbur A. Franklin,
Marileila VarellaGarcia,
Paul A. Bunn,
D. Ross Camidge
Publication year - 2011
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2010.34.4929
Subject(s) - erlotinib , medicine , lung cancer , carboplatin , erlotinib hydrochloride , epidermal growth factor receptor , oncology , chemotherapy , clinical endpoint , cancer , randomized controlled trial , cisplatin
Erlotinib prolongs survival in patients with advanced non-small-cell lung cancer (NSCLC). We report the results of a randomized, phase II study of erlotinib alone or intercalated with chemotherapy (CT + erlotinib) in chemotherapy-naïve patients with advanced NSCLC who were positive for epidermal growth factor receptor (EGFR) protein expression and/or with high EGFR gene copy number.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom